{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:00:28Z","timestamp":1780470028235,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with schizophrenia spectrum disorders are at elevated risk for developing opioid use disorder and often experience higher substance use rates and morbidity. However, integrated treatment models for such patients remain rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study addresses a gap in clinical knowledge by evaluating outcomes from a dual-diagnosis program tailored for patients with both disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective case series analyzed electronic medical record data from when patients were enrolled in the program through March 1\n                      <jats:sup>st<\/jats:sup>\n                      , 2025 or program discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients attended at least one appointment. All patients had a diagnosis of opioid use disorder. Co-occurring psychotic disorders included schizoaffective disorder (13\/17, 76%), schizophrenia (3\/17, 18%), and unspecified psychotic disorder (1\/17, 6%). On average, patients attended 58.8% of scheduled visits, and 47.1% remained actively enrolled as of 3\/1\/25. Medication adherence was high, with patients taking prescribed medications for opioid use disorder at 90.5% of visits and antipsychotics at 96.9% of visits. Compared to an equivalent pre-enrollment period, patients showed a significant reduction in emergency department visits (P=0.00051) and inpatient hospitalizations (P=0.00090).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings suggest that the integrated treatment model could offer benefits for patients with co-occurring opioid use disorder\/schizophrenia spectrum disorders; patients had significantly reduced emergency department visit frequency and frequency\/duration of hospitalizations. Patients demonstrated high adherence to medications for opioid use disorder and antipsychotics; appointment attendance remains an area for improvement. Further research with larger samples and longer follow-up is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1826744","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:01:02Z","timestamp":1780466462000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes of an integrated treatment model for patients with co-occurring opioid use and schizophrenia spectrum disorders"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongjia","family":"Deng","sequence":"first","affiliation":[{"name":"West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Seman","sequence":"additional","affiliation":[{"name":"West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Ma","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Moomaw","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Durham-Vold","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolbi","family":"Tonkovich","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hustead","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, West Virginia University School of Public Health","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4303\/JDAR\/236234","article-title":"Opioid dependence in schizophrenia: Understanding the co-occurrence and implications","volume":"12","author":"Altable","year":"2023","journal-title":"J Drug Alcohol Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","article-title":"Emergency department visits related to schizophrenia among adults aged 18-64: United States, 2009-2011","volume":"215","author":"Albert","year":"2015","journal-title":"NCHS Data Brief"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/ADT.0b013e318227ecdc","article-title":"Protocols of dual diagnosis intervention in schizophrenia","volume":"10","author":"Roncero","year":"2011","journal-title":"Addict Disord Their Treat"},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12991-024-00529-7","article-title":"Management of schizophrenia and comorbid substance use disorders: Expert review and guidance","volume":"23","author":"Neyra","year":"2024","journal-title":"Ann Gen Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13040999","article-title":"Navigating the complex intersection of substance use and psychiatric disorders: a comprehensive review","volume":"13","author":"Bahji","year":"2024","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199605060-00002","article-title":"Dual diagnosis in patients with schizophrenia","volume":"5","author":"Soyka","year":"1996","journal-title":"CNS Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2024.2315366","article-title":"10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder","volume":"43","author":"Zheng","year":"2025","journal-title":"J Addict Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/cpr.14.34","article-title":"Appointment attendance in patients with schizophrenia","volume":"11","author":"Daniels","year":"2014","journal-title":"Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1182441","article-title":"Poverty and inequality in real-world schizophrenia: a national study","volume":"11","author":"Fond","year":"2023","journal-title":"Front Public Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-018-1552-8","article-title":"Social networks and symptomatic and functional outcomes in schizophrenia: A systematic review and meta-analysis","volume":"53","author":"Degnan","year":"2018","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgaa007","article-title":"Psychosis and comorbid opioid use disorder: Characteristics and outcomes in opioid substitution therapy","volume":"1","author":"Lamont","year":"2020","journal-title":"Schizophr Bull Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1207","article-title":"Trends in buprenorphine initiation and retention in the United States, 2016-2022","volume":"329","author":"Chua","year":"2023","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000287","article-title":"Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"J Addict Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200570","article-title":"First-episode psychosis and disengagement from treatment: a systematic review","volume":"65","author":"Doyle","year":"2014","journal-title":"Psychiatr Serv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.9740\/mhc.2018.03.056","article-title":"Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis","volume":"8","author":"Titus-Lay","year":"2018","journal-title":"Ment Health Clin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst Abuse Rehabil"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addict Sci Clin Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000246","article-title":"Under-reporting of risky drug use among primary care patients in federally qualified health centers","volume":"10","author":"Bone","year":"2016","journal-title":"J Addict Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713000548","article-title":"Under-reporting of drug use among individuals with schizophrenia: Prevalence and predictors","volume":"44","author":"Bahorik","year":"2014","journal-title":"Psychol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1499","article-title":"Experienced continuity of care when patients see multiple clinicians: A qualitative metasummary","volume":"11","author":"Haggerty","year":"2013","journal-title":"Ann Fam Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.01.016","article-title":"Group treatment for substance use disorder in adults: a systematic review and meta-analysis of randomized-controlled trials","volume":"99","author":"Lo Coco","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1037\/a0034698","article-title":"Dyadic coregulation and deviant talk in adolescent friendships: Interaction patterns associated with problematic substance use in early adulthood","volume":"50","author":"Piehler","year":"2014","journal-title":"Dev Psychol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.2002.63.581","article-title":"Iatrogenic effects of alcohol and drug prevention programs","volume":"63","author":"Werch","year":"2002","journal-title":"J Stud Alcohol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2021.3.50839","article-title":"Emergency department visits by patients with substance use disorder in the United States","volume":"22","author":"Zhang","year":"2021","journal-title":"West J Emerg Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.1467","article-title":"Mental health service use before first diagnosis of a psychotic disorder","volume":"81","author":"Tempelaar","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/add.16401","article-title":"Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study","volume":"119","author":"van Hest","year":"2024","journal-title":"Addiction"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.0618","article-title":"Understanding patterns of high-cost health care use across different substance user groups","volume":"35","author":"Gryczynski","year":"2016","journal-title":"Health Aff Proj Hope"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/070674371105600307","article-title":"Increased risk of avoidable hospitalization among patients with schizophrenia","volume":"56","author":"Lin","year":"2011","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.06.006","article-title":"Antipsychotic adherence and emergency department utilization among patients with schizophrenia","volume":"201","author":"Hardy","year":"2018","journal-title":"Schizophr Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2003.tb00545.x","article-title":"Brief integrated outpatient dual-diagnosis treatment reduces psychiatric hospitalizations","volume":"12","author":"Granholm","year":"2003","journal-title":"Am J Addict"},{"key":"B36","volume-title":"Genes, environment, and psychopathology: understanding the causes of psychiatric and substance use disorders","author":"Kendler","year":"2007"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1826744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:01:04Z","timestamp":1780466464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1826744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2026.1826744"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1826744","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1826744"}}